There are also other prognostic biomarkers which have been evaluated for the imaging of triple-negative breast cancer in preclinical studies, such as syndecan-1 (CD138) (83) and IGF-1 (74). The gene discussed is SDC1; the disease is triple-negative breast carcinoma.